The $34 billion private equity powerhouse H.I.G. Capital announced the acquisition of BioVectra in a bid to further expand the Canadian company’s biopharmaceutical business.
The BioVectra leadership team has expanded its presence by expanding capacity with the support of Mallinckrodt Pharmaceuticals in recent years. BioVectra CEO Oliver Technow outlined the company’s growth trajectory that will be supported by H.I.G.
“We believe the company is well positioned to capitalize on the growing demand for its broad set of technical capabilities and exceptional quality track record,” said Mike Gallagher, managing director . . .
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.